ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease
- Author(s)
- Hamad, N; Bilmon, I; Chee, L; Henden, A; Johnston, A; Purtill, D; Bajel, A; Tey, SK; Yeung, D; Cole, T; Lewis, C; Butler, J;
- Details
- Publication Year 2023-12,Volume 53,Issue #12,Page 2319-2329
- Journal Title
- Internal Medicine Journal
- Publication Type
- Guideline
- Abstract
- This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.
- Publisher
- Wiley
- Keywords
- Humans; *Bronchiolitis Obliterans Syndrome; Consensus; *Hematopoietic Stem Cell Transplantation; Steroids/therapeutic use; Nitriles; Adrenal Cortex Hormones/therapeutic use; *Graft vs Host Disease/drug therapy; Acute Disease; Chronic Disease; GvHD; acute; chronic; graft-versus-host disease; ruxolitinib
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1111/imj.16255
- Open Access at Publisher's Site
- https://doi.org/10.1111/imj.16255
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-18 07:06:24
Last Modified: 2024-01-18 07:06:48